Sarepta Therapeutics, Inc.

Where It Passes

Where It Falls Short

• Valuation0% pass✓ 6✗ 22▾

  No clean pass — all 13 investors flag at least one valuation criterion

  Price / Book Value per Share1.5x

  ✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)

  Price / 3-yr avg EPS

  ✗Graham<= 15x

  Price-to-Book Ratio1.5x

  ✓Graham<= 1.5x

  P/E x P/B

  ✗Graham<= 22.5

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  EBIT / Enterprise Value-2.3%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=-2.3%, ROC=-3.3%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Price / EPS

  ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)

  Price / (CFO / Shares)N/A (negative CFPS)

  ✗Dreman< 8x

  Valuation ReasonablenessOE Yield=-45.8%

  ✗MungerP/E < 25 or Owner Earnings Yield > 5%

  P/E or FCF YieldFCF Yield=-17.8%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  P/B or P/E vs. Historical AverageP/B=1.5x

  ✓MarksP/E < 15 or P/B < 2.0

  Discount to Intrinsic ValueN/A (negative normalized EPS)

  ✗Marks>= 20% below intrinsic value

  Price / FCF per ShareN/A (negative FCF)

  ✗Ackman<= 25

  Price vs. Trailing Low100% of trailing low ($16.07)

  ✓Templeton<= 120% of trailing low (certified split-adjusted live window)

  Net income / market capitalization-6.65%; #3993/6340 (top 63.0%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Positive book equity / market capitalization+0.8872; #1707/6449 (top 26.5%)

  ✓AsnessTop 30% of eligible cross-section

  Price / Diluted EPS

  ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)

  (EPS CAGR % + Dividend Yield %) / P/E

  ✗Neff> 0.7 (Neff's published traditional edge)

  Price / Tangible Book Value per Share1.51x

  ✗SchlossP/TBV <= 1.00x (app cutoff)

  Book Value per Share Change+13.6%

  ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)

  Revenue / market capitalization+1.1352; #1637/5247 (top 31.2%)

  ✗OshaughnessyTop 10% of eligible cross-section

  (Operating cash flow - capex) / market capitalization+10.24%; #737/4519 (top 16.3%)

  ✗OshaughnessyTop 10% of eligible cross-section

  Trailing six-month price return through the evaluation date-24.13%; #4170/6202 (top 67.2%)

  ✗OshaughnessyTop 10% of eligible cross-section
• Profitability6% pass✓ 4✗ 31▾

  15 of 16 flag SRPT's profitability — Graham, Buffett, Lynch +12 more

  Positive EPS (10 years)1/28 years positive

  ✗GrahamPositive EPS every year for 10 years

  EPS Growth (3-yr avg, 10-yr window)

  ✗Graham>= 33% growth

  Net Income Positive (10+ years)1/28 years positive

  ✗BuffettPositive every year for 10+ years

  ROE (up to 5-year arithmetic mean)-67.5%

  ✗Buffett> 15% arithmetic mean (app rule)

  Operating Margin (10-yr trend)-31.8% (latest)

  ✓BuffettStable or rising over 10 years

  Free Cash Flow Proxy$-724.3M

  ✗BuffettPositive and growing

  Earnings Variance (10-yr CoV)N/A (negative mean EPS)

  ✗BuffettCoV < 0.3

  Retained Earnings Effectiveness

  ✗Buffett$1 retained -> > $1 market value created

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  ROE-7.5%

  ✗Lynch> 15%

  EBIT / Enterprise Value-2.3%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=-2.3%, ROC=-3.3%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Net Income / Total Assets-21.30%

  ✗PiotroskiROA > 0

  ROA Change YoY5.94% -> -21.30% (delta: -27.23%)

  ✗PiotroskiCurrent ROA > Prior ROA

  (CFO / Total Assets) vs ROACFO/Assets=-6.13%, ROA=-21.30%

  ✓PiotroskiCFO/Assets > ROA

  Gross Margin Change YoY

  ✗PiotroskiImproved YoY

  Pre-Tax Income / Revenue1.9%

  ✗Dreman>= 8%

  Net Income / Shareholders' Equity-7.5%

  ✗Dreman> 12%

  Margin of SafetyP/B=1.5x

  ✓PabraiP/B < 1.5 or P/E < 15

  Return on Equity-36.5% (3-yr avg)

  ✗AkreROE > 20% (3-year avg)

  Discount to Intrinsic ValueN/A (negative normalized EPS)

  ✗Marks>= 20% below intrinsic value

  Positive Net Income Frequency1/17 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  Operating Income / Revenue-2.5%

  ✗Ackman>= 15%

  Net Income / Shareholders Equity-7.5%

  ✗Ackman>= 15%

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Operating Margin Trend-21.5% (2023) -> -31.8% (2025)

  ✗TempletonNon-negative operating-margin trend over 3 years

  Revenue growth vs. gross and operating margin trendrevenue up, operating margin -21.5% -> -31.8%

  ✗SleepRevenue rising; gross margin flat or falling; operating margin holding

  Net income / market capitalization-6.65%; #3993/6340 (top 63.0%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Gross profit / total assets+64.86%; #405/3702 (top 10.9%)

  ✓AsnessTop 30% of eligible cross-section

  Net income / positive book equity-7.50%; #3309/5226 (top 63.3%)

  ✗AsnessTop 30% of eligible cross-section

  Negative 5-year standard deviation of ROA-0.1027; #3515/5884 (top 59.7%)

  ✗AsnessTop 30% of eligible cross-section

  3-5 Year Diluted EPS CAGR

  ✗Neff7%-20% annualized

  Positive Diluted-EPS Years1/10 years positive

  ✗Schloss>= 70% positive over 5-10 observed years (app rule)
• Growth13% pass✓ 3✗ 10▾

  7 of 8 flag SRPT's growth — Graham, Lynch, Dreman +4 more

  EPS Growth (3-yr avg, 10-yr window)

  ✗Graham>= 33% growth

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  Inventory Growth vs Revenue GrowthInv: -18.7% vs Rev: -18.9%

  ✗LynchInventory growth < Revenue growth

  EPS Growth Direction$-0.27 (2009) -> $-7.13 (2025)

  ✗DremanPositive over recent years

  EPS CAGR

  ✗Dreman> 5% annualized

  Positive Net Income Frequency1/17 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  3yr Median Revenue Growth33.3%

  ✓Ackman>= 5%

  Positive EPS Growth Frequency3/5 years with positive EPS growth

  ✓AckmanPositive EPS growth in >= 3 of last 5 years

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Revenue growth vs. gross and operating margin trendrevenue up, operating margin -21.5% -> -31.8%

  ✗SleepRevenue rising; gross margin flat or falling; operating margin holding

  5-year Revenue CAGR32.4%

  ✓SleepCAGR > 7%

  3-5 Year Diluted EPS CAGR

  ✗Neff7%-20% annualized
• Verdicts19% pass✓ 3✗ 13▾

  Split decision: 12 FAIL · 3 PASS · 1 NEUTRAL

  Overall verdict

  ✓GrahamPASS (4/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #1935✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (3/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✓AckmanPASS (5/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1393/2370 (Top 58.8%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
• Cash Flow20% pass✓ 4✗ 8▾

  8 of 10 flag SRPT's cash flow — Buffett, Piotroski, Dreman +5 more

  Free Cash Flow Proxy$-724.3M

  ✗BuffettPositive and growing

  FCF Positive and Growing$176.4M

  ✓LynchPositive and growing

  Operating Cash Flow$-205.5M

  ✗PiotroskiCFO > 0

  (CFO / Total Assets) vs ROACFO/Assets=-6.13%, ROA=-21.30%

  ✓PiotroskiCFO/Assets > ROA

  Price / (CFO / Shares)N/A (negative CFPS)

  ✗Dreman< 8x

  P/E or FCF YieldFCF Yield=-17.8%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  FCF Positive1/17 years FCF positive

  ✗MarksPositive FCF in majority of recent years

  (OCF - CapEx) / Market Cap10.5%

  ✓Ackman>= 4%

  Price / FCF per ShareN/A (negative FCF)

  ✗Ackman<= 25

  Positive Operating Cash Flow frequency1/17 years positive

  ✗SleepPositive OCF in >= 70% of available years

  Operating Cash Flow - Capital Expenditures$176.4M

  ✓Neff> $0 (app proxy for a strong fundamental case)

  (Operating cash flow - capex) / market capitalization+10.24%; #737/4519 (top 16.3%)

  ✗OshaughnessyTop 10% of eligible cross-section
• Efficiency25% pass✓ 3✗ 8▾

  6 of 8 flag SRPT's efficiency — Buffett, Greenblatt, Piotroski +3 more

  Current Ratio3.46

  ✓Graham>= 2.0

  ROIC (3-5 yr avg)-23.6%

  ✗Buffett> 10%

  ROIC - WACC-33.6%

  ✗BuffettPositive (WACC = 10%)

  EBIT / (NWC + Net Fixed Assets)-3.3%

  ✗Greenblatt> 25%

  Current Ratio Change YoY4.20 -> 2.32

  ✗PiotroskiIncreased YoY

  Revenue / Total Assets Change YoY0.48x -> 0.66x

  ✓PiotroskiImproved YoY

  Current Assets / Current Liabilities3.46

  ✓Dreman> 1.5

  Return on Invested Capital-1.6%

  ✗Munger> 15%

  ROIC (high and growing)FY2023: ROIC=-10.1%; FY2024: ROIC=6.5%; FY2025: ROIC=-28.1%

  ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each

  Reinvestment Rate x ROICN/A (non-positive net income)

  ✗AkreReinvestment Rate * ROIC > 10%

  ROIC (5-year)0/5 years above 12% (latest -28.1%)

  ✗SleepROIC > 12% in a majority of years
• Debt & Leverage50% pass✓ 8✗ 7▾

  6 of 12 pass — Buffett, Lynch, Munger +3 more object

  LT Debt vs Net Current AssetsLT Debt $857.4M vs NCA $1.6B

  ✓GrahamLT Debt <= Net Current Assets

  Debt/Equity & Interest CoverageD/E: 0.56, IC: -0.8x

  ✗BuffettD/E < 0.5 AND Interest Coverage > 5x

  Total Debt / Equity0.56

  ✗Lynch< 0.33

  Cash - Long-term Debt$-384.6M

  ✗LynchPositive preferred

  LT Debt / Total Assets Change28.69% -> 24.75%

  ✓PiotroskiDecreased YoY

  Current Assets / Current Liabilities3.46

  ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)

  Total Debt / Shareholders' Equity0.56

  ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x

  Debt Levels0.56

  ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3

  Interest Coverage & Debt/EBITDA

  ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x

  Total Debt / Shareholders Equity0.56

  ✓Ackman<= 1.0

  Negative debt-to-equity (higher means less debt)-0.5608; #2588/4210 (top 61.5%)

  ✗AsnessTop 30% of eligible cross-section